
- The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day volume of 283.18 thousand shares, closed regular trading session at $1.67. The company shares are currently trading at $1.77, up 5.99 percent in the after-hours trading session.
- Alnylam (NASDAQ:ALNY) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Alnylam shares traded in a range of $198 to $220.92 on a day volume of 8.54 million shares, closed regular trading session at $212.01.